In today’s briefing:
- Akeso Biopharma Placement (9926.HK) – The Concerns Behind and the Outlook
- Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch
Akeso Biopharma Placement (9926.HK) – The Concerns Behind and the Outlook
- The current stock price is not high. Akeso is reluctant to diluting its shareholders too much. So, it plans to raise just HK$576.65 million, which won’t bring any fundamental change.
- Akeso (9926 HK)’s conservative management style, development mode, low cash balance and FDA’s “Guidance” on bispecific antibodies would limit the Company’s future development pace, commercialization, internationalization and valuation expansion prospects.
- We do not think Akeso is attractive at present, unless the Company could hit some big license-out deals, or IPO on SSE STAR Market to secure enough funds in advance.
Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch
- Aztiq and Innobic have formally become the leading shareholder of Lotus Pharmaceutical (1795 TT), with the controlling stake of 51%. New ownership will accelerate the growth and expansion of Lotus.
- Lotus has created a niche for itself through its focus on oral oncology drug. Launch of Lenalidomide in 14 European countries drove 31% q/q growth in export revenue in Q1.
- Continued strong uptake of the company’s newly acquired drug Cialis in Taiwan and bevacizumab biosimilar launch in Korea and Taiwan should boost its Asian business revenue.
Before it’s here, it’s on Smartkarma
